How should paclitaxel (Pacliaqualip) and cisplatin be administered on a weekly schedule?

Weekly Paclitaxel and Cisplatin Administration

For weekly paclitaxel and cisplatin administration, the recommended regimen is paclitaxel 60 mg/m² IV over 1 hour followed by cisplatin 20-25 mg/m² IV over 30 minutes, given weekly for 18 weeks (or until disease progression/toxicity). This represents a Category 1 recommendation for ovarian cancer and has been validated across multiple tumor types 1.

Specific Dosing Schedules by Clinical Context

Ovarian/Fallopian Tube/Primary Peritoneal Cancer (Category 1)

• Paclitaxel 60 mg/m² IV over 1 hour
• Carboplatin AUC 2 IV over 30 minutes (note: carboplatin, not cisplatin, is the preferred platinum agent for this weekly schedule)
• Weekly for 18 weeks 1

This regimen is equivalent in efficacy to standard every-3-week dosing but may offer better tolerability in elderly or frail patients 2.

Alternative Weekly Cisplatin-Based Regimens

For contexts where cisplatin (rather than carboplatin) is specifically indicated:

Standard Weekly Dose:

• Paclitaxel 80 mg/m² IV over 1 hour
• Cisplatin 20-25 mg/m² IV over 30 minutes
• Weekly administration 3, 4, 5, 6

Dose Escalation Data:

• Maximum tolerated doses with G-CSF support: paclitaxel 85 mg/m² + cisplatin 40 mg/m² weekly 6, 7
• Without G-CSF: paclitaxel 65 mg/m² + cisplatin 30 mg/m² weekly 6

Administration Details

Sequencing

Always administer paclitaxel first, followed by cisplatin 6, 7. This sequence is critical for optimal efficacy and toxicity management.

Premedication for Paclitaxel

• Dexamethasone 20 mg IV 30-60 minutes before
• Diphenhydramine 50 mg IV 30-60 minutes before
• H2-antagonist (ranitidine 50 mg or famotidine 20 mg) IV 30-60 minutes before

Hydration for Cisplatin (Critical)

Even with weekly low-dose cisplatin:

• Pre-hydration: 500-1000 mL normal saline over 1-2 hours before cisplatin
• Post-hydration: Maintain adequate oral intake or IV fluids for 24 hours
• Monitor renal function before each dose 8

Infusion Rates

• Paclitaxel: 1-hour infusion (not 3 hours as with every-3-week dosing)
• Cisplatin: 30-minute to 1-hour infusion 3, 4, 5

Treatment Duration and Monitoring

Duration

• 18 weeks is the standard duration for ovarian cancer 1
• Continue until disease progression, unacceptable toxicity, or completion of planned cycles
• Some protocols use 6-week cycles with reassessment 5, 7

Mandatory Monitoring Before Each Dose

• CBC with differential: Hold if ANC <1,500/mm³ or platelets <100,000/mm³
• Serum creatinine: Hold if >1.5 mg/dL 8
• Neurologic assessment: Dose reduce or discontinue for grade ≥2 neuropathy

Dose Modifications

For Hematologic Toxicity:

• Grade 3-4 neutropenia: Reduce paclitaxel by 20% or add G-CSF support
• Grade 3-4 thrombocytopenia: Hold until recovery, then reduce both agents by 20%

For Neurotoxicity:

• Grade 2 sensory neuropathy: Reduce paclitaxel to 60 mg/m² (if starting at 80 mg/m²)
• Grade 3 neuropathy: Discontinue paclitaxel; consider cisplatin alone or alternative regimen

For Renal Toxicity:

• Creatinine 1.5-2.0 mg/dL: Reduce cisplatin by 50%
• Creatinine >2.0 mg/dL: Hold cisplatin until recovery to <1.5 mg/dL 8

Key Toxicity Considerations

Expected Toxicities (Weekly Schedule)

• Anemia: More common with weekly dosing (36% grade 3-4) 9
• Neutropenia: Less severe than every-3-week dosing (72% vs 83% grade 3-4) 9
• Peripheral neuropathy: Cumulative; occurs in 18-26% (grade 2-4) 5, 9
• Ototoxicity: Monitor audiometry if prolonged cisplatin exposure 8

Critical Safety Points

• Never use aluminum-containing needles or IV sets with cisplatin (causes precipitation and loss of potency) 8
• Anaphylaxis risk: Have epinephrine, corticosteroids, and antihistamines immediately available 8
• Extravasation: Cisplatin concentrations >0.5 mg/mL can cause severe tissue necrosis; use central access if available 8

Clinical Context Considerations

Elderly/Frail Patients

The weekly paclitaxel 60 mg/m² + carboplatin AUC 2 schedule is specifically recommended for elderly patients or those with poor performance status, offering better tolerability and quality of life 2.

Prior Chemotherapy Exposure

In pretreated patients, start at lower doses:

• Paclitaxel 75 mg/m² (instead of 80-85 mg/m²)
• Cisplatin 20 mg/m² (instead of 25 mg/m²)
• Neurotoxicity is more frequent and severe in cisplatin-pretreated patients 6, 7

G-CSF Support

Consider prophylactic G-CSF (5 mcg/kg SC days 3-5 of each week) if:

• Prior extensive chemotherapy
• Baseline neutropenia
• Dose escalation beyond standard weekly doses 6, 7